The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The article highlights various financial dynamics within the pharmaceutical industry amid prevailing economic conditions.

Stock market outlook dims today with S&P 500 futures down. Pre-market analysis highlights trade tensions and sector rebalancing risks.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday. Skechers reported quarterly earnings of $1.34 per share, which beat the analyst consensus ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

US stocks open little changed as investors parse mixed trade signals from Trump and China. Alphabet tops earnings ...

This visceral drama felt like the definitive show of the first Trump presidency. But, argues Fiona Sturges, the further it’s ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...